

# Carlo Briguori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3403796/publications.pdf>

Version: 2024-02-01

90  
papers

4,286  
citations

201674

27  
h-index

110387

64  
g-index

92  
all docs

92  
docs citations

92  
times ranked

4701  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	27.0	683
2	Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL). <i>Circulation</i> , 2007, 115, 1211-1217.	1.6	438
3	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 373, 997-1009.	27.0	334
4	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1608-1618.	27.0	310
5	Novel Approaches for Preventing or Limiting Events (Naples) II Trial. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2157-2163.	2.8	223
6	Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II). <i>Circulation</i> , 2011, 124, 1260-1269.	1.6	217
7	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet</i> , 2018, 392, 835-848.	13.7	215
8	Cystatin C and Contrast-Induced Acute Kidney Injury. <i>Circulation</i> , 2010, 121, 2117-2122.	1.6	212
9	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 426-436.	2.9	135
10	Ticagrelor With or Without Aspirin After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	2.8	122
11	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	2.2	93
12	Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. <i>FASEB Journal</i> , 2010, 24, 1981-1988.	0.5	80
13	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	2.8	60
14	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.	2.2	54
15	Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in Italy: the IMP-IT registry. <i>EuroIntervention</i> , 2020, 15, e1343-e1350.	3.2	51
16	Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1166-1175.	2.9	49
17	Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCI. <i>International Journal of Cardiology</i> , 2019, 293, 84-90.	1.7	46
18	Novel Approaches for Preventing or Limiting Events (Naples) III Trial. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 414-423.	2.9	45

#	ARTICLE	IF	CITATIONS
19	Nephrotoxicity of contrast media and protective effects of acetylcysteine. Archives of Toxicology, 2011, 85, 165-173.	4.2	41
20	Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial. Circulation: Cardiovascular Interventions, 2011, 4, 121-129.	3.9	41
21	Novel Biomarkers for Contrast-Induced Acute Kidney Injury. BioMed Research International, 2014, 2014, 1-5.	1.9	41
22	RenalGuard system in high-risk patients for contrast-induced acute kidney injury. American Heart Journal, 2016, 173, 67-76.	2.7	39
23	Neutrophil Gelatinase-Associated Lipocalin and Contrast-Induced Acute Kidney Injury. Circulation: Cardiovascular Interventions, 2015, 8, e002673.	3.9	38
24	Mid-term outcomes after percutaneous interventions in coronary bifurcations. International Journal of Cardiology, 2019, 283, 78-83.	1.7	33
25	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. Journal of the American College of Cardiology, 2018, 71, 1231-1242.	2.8	32
26	Myocardial hypoxic stress mediates functional cardiac extracellular vesicle release. European Heart Journal, 2021, 42, 2780-2792.	2.2	32
27	Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007311.	3.9	30
28	Left Ventricular End-Diastolic Pressure Versus Urine Flow Rate-Guided Hydration in Preventing Contrast-Associated Acute Kidney Injury. JACC: Cardiovascular Interventions, 2020, 13, 2065-2074.	2.9	29
29	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	2.9	27
30	RenalGuard System for the prevention of acute kidney injury in patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 11, e1658-e1661.	3.2	27
31	One-year clinical outcome of amphilius polymer-free drug-eluting stent in diabetes mellitus patients. International Journal of Cardiology, 2016, 214, 113-120.	1.7	25
32	Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Internal Carotid Artery Stent Implantation. JACC: Cardiovascular Interventions, 2015, 8, 1506-1514.	2.9	24
33	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation, 2021, 144, 1380-1395.	1.6	24
34	Contrast-induced acute kidney injury. Current Opinion in Nephrology and Hypertension, 2015, 24, 145-153.	2.0	23
35	Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EuroIntervention, 2011, 6, 1117-1122.	3.2	22
36	The STENTYS® paclitaxel-eluting stent in the treatment of unprotected distal left main. Catheterization and Cardiovascular Interventions, 2015, 86, E131-9.	1.7	21

#	ARTICLE	IF	CITATIONS
37	Urinary Dickkopf-3 and Contrast-Associated Kidney Damage. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2667-2676.	2.8	18
38	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	2.2	18
39	Device-related complications after Impella mechanical circulatory support implantation: an IMP-IT observational multicentre registry substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 999-1006.	1.0	16
40	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULTimaster Italian multicenter all comerS Stent rEgistry). <i>International Journal of Cardiology</i> , 2018, 260, 36-41.	1.7	15
41	Hydration in contrast-induced acute kidney injury. <i>Lancet, The</i> , 2014, 383, 1786-1788.	13.7	13
42	Impact of a contrast media volume control device on acute kidney injury rate in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 76-84.	1.7	13
43	Safety and feasibility of balloon aortic valvuloplasty in nonâ€TAVI centers: The â€BAV for lifeâ€ experience. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E63-E70.	1.7	12
44	Impact of Insulin-Treated and Noninsulin-Treated Diabetes Mellitus in All-Comer Patients Undergoing Percutaneous Coronary Interventions With Polymer-Free Biolimus-Eluting Stent (from the RUDI-FREE) Tj ETQq0 0 0 rgBT/Overload 10 Tf 50	1.7	12
45	Biomarkers of Contrast-Induced Nephropathy:. <i>Interventional Cardiology Clinics</i> , 2020, 9, 335-344.	0.4	12
46	Recalcitrant inâ€stent restenosis of the celiac trunk treated by drugâ€eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 873-876.	1.7	11
47	Renalguard system: A dedicated device to prevent contrast-induced acute kidney injury. <i>International Journal of Cardiology</i> , 2013, 168, 643-644.	1.7	11
48	Midterm and one-year outcome of amphilius polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (Amphilimus iTalian mUlticenter) Tj ETQq0 0 0 rgBT/Overload 10 Tf 50	1.7	11
49	Clinical outcomes with reservoirâ€based polymerâ€free amphiliusâ€eluting stents in realâ€world patients according to diabetes mellitus and complexity: The INVESTIG8 registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 884-891.	1.7	11
50	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 533-541.	1.7	11
51	Tailored Versus Standard Hydration to Prevent Acute Kidney Injury After Percutaneous Coronary Intervention: Network Metaâ€Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e021342.	3.7	11
52	Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: Randomised Comparison of Bivalirudin Versus Unfractionated Heparin in Patients at High Risk of Bleeding Undergoing Elective Coronary Stenting Through The Femoral Approach. Rationale and Design. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 273-279.	2.6	10
53	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. <i>International Journal of Cardiology</i> , 2017, 244, 112-118.	1.7	10
54	Renal insufficiency following contrast media administration trial III: Urine flow rateâ€guided versus leftâ€ventricular endâ€diastolic pressureâ€guided hydration in highâ€risk patients for contrastâ€induced acute kidney injury. Rationale and design. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 895-903.	1.7	10

#	ARTICLE	IF	CITATIONS
55	The CID Chrono, cobalt-chromium alloy carbofilm-coated coronary stent system. <i>International Journal of Cardiology</i> , 2011, 149, 199-204.	1.7	9
56	Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins. <i>International Journal of Hypertension</i> , 2011, 2011, 1-12.	1.3	9
57	Persistent serum creatinine increase following contrast-induced acute kidney injury. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1185-1191.	1.7	9
58	The impact of the extent of side branch disease on outcomes following bifurcation stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E84-E92.	1.7	8
59	In Vivo Histological Assessment of a Spontaneous Coronary Artery Dissection. <i>Circulation</i> , 2010, 122, 1044-1046.	1.6	7
60	Endothelial progenitor cells in coronary artery disease. <i>Biological Chemistry</i> , 2013, 394, 1241-1252.	2.5	7
61	Coronary artery bifurcation narrowing treated by Axxess stent implantation: The CARINAX registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E112-E123.	1.7	7
62	One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients. <i>Journal of the American Heart Association</i> , 2022, 11, e023454.	3.7	7
63	The glider balloon: A useful device for the treatment of bifurcation lesions. <i>International Journal of Cardiology</i> , 2013, 168, 3208-3211.	1.7	6
64	Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 63-71.	1.7	6
65	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. <i>Journal of the American Heart Association</i> , 2022, 11, e022003.	3.7	6
66	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 972-979.	1.7	5
67	Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1418-1428.	1.2	5
68	Sirolimus-eluting BiOSS LIM dedicated bifurcation stent in the treatment of unprotected distal left main stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 323-331.	1.7	5
69	Paclitaxel versus sirolimus-coated balloon in the treatment of coronary in-stent restenosis. <i>Panminerva Medica</i> , 2023, 65, .	0.8	5
70	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 707-716.	3.0	5
71	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	3.2	5
72	DyeVert Contrast Reduction System Use in Patients Undergoing Coronary and/or Peripheral Angiography: A Systematic Literature Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 841876.	2.6	5

#	ARTICLE	IF	CITATIONS
73	Prospective evaluation of drug eluting self-expanding stent for the treatment of unprotected left main coronary artery disease: 1-year results of the TRUNC study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E142-E148.	1.7	4
74	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULTimaster Italian multicenter all comerS Stent rEgistry). <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 255-265.	1.7	4
75	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 934-936.	5.3	3
76	Predictors of strut coverage of drug eluting stent implantation in diabetic patients. <i>International Journal of Cardiology</i> , 2019, 276, 61-65.	1.7	3
77	Preoperative evaluation of caseous calcification of the mitral annulus by TrueVue transillumination rendering. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 1697-1698.	1.5	3
78	Elective Mechanical Circulatory Support in the Percutaneous Treatment of Patients With Combined Complex Coronary Artery Disease and Severe Aortic Valve Stenosis. <i>Journal of Invasive Cardiology</i> , 2019, 31, 52-56.	0.4	3
79	The Avantgarde Carbostent in Patients Scheduled for Undelayable Noncardiac Surgery. <i>Thrombosis</i> , 2012, 2012, 1-6.	1.4	2
80	Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1156-1171.	1.7	2
81	Left ventricular support during complex transradial percutaneous coronary intervention for complete revascularization. <i>Minerva Cardioangiologica</i> , 2019, 67, 348-355.	1.2	2
82	Statins and contrast-induced acute kidney injury. <i>Coronary Artery Disease</i> , 2014, 25, 550-551.	0.7	1
83	Outcomes of the amphimus-eluting polymer-free stent for chronic total occlusion treatment. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 564-570.	1.5	1
84	Predictors of strut coverage of drug eluting stent implantation in diabetic patients- Is only on-clopidogrel platelet reactivity enough? Reply. <i>International Journal of Cardiology</i> , 2019, 283, 95.	1.7	1
85	Stent thrombosis in patients with chronic kidney disease. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 617-626.	1.5	0
86	Endothelial Progenitor Cells and Percutaneous Coronary Artery Intervention. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 105-106.	2.6	0
87	STENTYS coronary system: current status and future direction. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 201-214.	0.7	0
88	Early P2Y <sub>12</sub> Receptor Monotherapy Following Drug-Eluting Stenting: Is It Time to Give Up Aspirin?. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010880.	3.9	0
89	The "locking and dragging" technique a facilitated crossover balloon occlusion technique for complex iliofemoral anatomy in transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E968-E970.	1.7	0
90	Nonpulsatile Systemic Flow During Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock. , 2022, , 100384.		0